A recombinant signallingselective activated protein C that lacks anticoagulant activity is efficacious and safe in cutaneous wound preclinical models
Call us or request an appointment online today.
For infants up to 12 months, the adequate intake (AI) is 0.40.5 g/day
The FDA does not review or approve any compounded medications for safety or effectiveness
The disclosure also contemplates the use of one or more of the formulations or compositions, in the manufacture of medicaments for treating, abating, reducing, or ameliorating the symptoms of a disease, dysfunction, or disorder in a mammal, such as a human that has, is suspected of having, or at risk for developing an auris interna disorder